Clinical Research Directory

Inclusion Criteria: * Males, aged \>= 45 years * Willing and able to provide written informed consent, including willingness to undergo MRI-targeted biopsy using OmnEcoil investigational system * Persistently elevated (\> 3 ng/mL) or rising prostate specific antigen (PSA) level and/or abnormal digital rectal exam * Prior negative transrectal ultrasound (TRUS) biopsy, or prior TRUS biopsy or transurethral resection of the prostate showing Gleason score =\< 6 disease * Received multiparametric prostate MRI within last 6 months prior to study enrollment with images available on Oregon Health and Science University (OHSU) image viewing system for review * Must have at least one high-value biopsy target (i.e., score of 4 or 5 as categorized by Prostate Imaging and Reporting and Data System \[PI-RADS\] version 2.1) present on multiparametric MRI as evaluated by study radiologists * Eastern Cooperative Group (ECOG) performance score 0 or 1 * Patient able to lie prone in MRI for OmnEcoil biopsy procedure * Considered to be low bleeding risk \[per Society for Interventional Radiology\], including: * International normalized ratio (INR) \<= 1.5, and * Platelets \>= 50,000 Exclusion Criteria: * Contraindication to MRI (e.g., severe claustrophobia, intracranial aneurysm clips, intraocular metallic foreign body, and cardiac pacemaker) * Any contraindication to endorectal devices and/or biopsy, including (but not limited to) severe hemorrhoids, anal fissure, recent rectal surgery, or prior abdominoperineal resection * Any bleeding diathesis and/or anti-coagulative therapy that cannot be temporarily reversed * Active infection requiring systemic antibiotic therapy. Participants requiring systemic antibiotics for infection must have completed antibiotic therapy before initiating OmnEcoil imaging/biopsy procedure * Administration of treatment for prostate cancer such as radiation or hormonal therapy prior to MRI-targeted biopsy * Uncontrolled intercurrent illness that would substantially increase risk of incurring adverse events (AEs), confound results, or compromise the ability of the patient to give written informed consent * Subjects unwilling to accept a blood transfusion